Gabapentinoid Exposure and Persistent Postoperative Opioid Use After Lumbar Spinal Fusion: A Systematic Review and Meta-Analysis
In brief
Gabapentinoids showed no link to persistent opioid use after lumbar fusion
Across six retrospective studies, gabapentinoid exposure was not associated with persistent opioid use after lumbar fusion, either at 3 to 6 months or at the longest follow-up. Studies also found no significant differences in inpatient opioid use or disability at 12 months. Because the evidence is observational, it does not establish that gabapentinoids reduce long-term opioid use.
- Journal
- International journal of spine surgery (Q1)
- Published
- 18 November 2026
- Study design
- Systematic review of cohort studies
- Evidence level
- Level 2, Moderate (CEBM 2a)
- Authors
- Matheus Loiola Magalhães Alves, Antônio Olímpio da Silva Moura Costa, Vinicius de Meldau Benites, Ana Camila de Castro Gandolfi, José Otávio Donadeli Tomé, Luciano Miller Reis Rodrigues, et al.
- PMID
- 43052000
- DOI
- 10.14444/8993
Why clinicians should know about it
- Picked for Spine Surgery (top studies of the week, 22 November 2026): Systematic review of gabapentinoids after lumbar fusion
Abstract
BACKGROUND: Gabapentinoids are used in multimodal analgesia, but their association with persistent opioid use after lumbar fusion remains uncertain. This systematic review and meta-analysis compared adults exposed to gabapentin or pregabalin with unexposed patients. The primary outcome was persistent opioid use or prescription. Inpatient opioid consumption, postoperative pain, and disability were assessed as secondary outcomes. METHODS: The PubMed, Embase, and the Cochrane Library databases were searched through 30 August 2026. Comparative studies of adults undergoing spinal fusion were eligible if they evaluated gabapentinoid exposure vs no exposure under usual care or a comparable opioid-based regimen. Two reviewers independently selected studies, extracted data, and assessed risk of bias using ROBINS-I. Cohorts with a high probability of overlap were not included together in the same pooled estimates. Random-effects models estimated risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). RESULTS: Six retrospective cohort studies involving patients undergoing lumbar fusion were included. Gabapentinoid exposure was not significantly associated with persistent opioid use or prescription at the longest compatible follow-up (RR, 1.03; 95% CI, 0.89-1.19; P = 0.67) or at 3-6 months (RR, 1.03; 95% CI, 0.81-1.32; P = 0.73). There were also no significant differences in inpatient opioid consumption (MD, 43.13 morphine milligram equivalents; 95% CI, -9.72 to 95.99; P = 0.07) or change in the Oswestry Disability Index at 12 months (MD, 2.73 points; 95% CI, -8.54 to 14.00; P = 0.41). Findings for persistent opioid use were consistent in temporal and publication-level sensitivity analyses. CONCLUSIONS: Observational evidence showed no statistically significant association between gabapentinoid exposure and persistent opioid use or prescription after lumbar fusion. There were also no significant differences in inpatient opioid consumption or 12-month changes in back pain, leg pain, or disability scores. CLINICAL RELEVANCE: Gabapentinoid use should remain individualized; these findings do not establish a benefit in reducing long-term opioid use after lumbar fusion. REGISTRATION: PROSPERO CRD420261493895.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.